Phase 4
Completed N=60
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Source: ClinicalTrials.gov NCT06533527 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcomePrimary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
◆ Published Evidence
Highly cited
239citations · ~80 / year
Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.
Summary
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
Primary Outcomes:
* Residual gastric volume that precludes adequate endoscopic examination
* Residual gastric volume that necessitates premature termination of the endoscopy procedure
* Need for endotracheal intubation due to stomach contents.
* Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hospital admission
Secondary Outcomes:
* Presence of any solid food
* Presence of moderate liquid content
* Increased RGV(Residual Gastric Volume) defined as any amount of solid content or > 0.8 mL/Kg of fluid content (measured from the aspiration/suction canister).
* Differences in primary and secondary outcomes between different medications
Linked Publications (3)
-
Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.
-
Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
-
Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Presence of RGV (Residual Gastric Volume) in Stomach |
7; 1 | — |
| PRIMARY Tracking the Use of Intubation Due to RGV |
0; 0 | — |
| PRIMARY Aspiration Events Due to RGV (Residual Gastric Volume) |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients using incretin-based therapies at a stable dose for more than 1 month.
- Patients scheduled for outpatient esophagogastroduodenoscopy (EGD), endoscopic ultrasound (EUS), or endoscopic retrograde cholangiopancreatography (ERCP) under monitored anesthesia care.
Exclusion Criteria
- Documented history of gastroparesis (based on a 4-hour solid-phase gastric emptying study)
- Known history of achalasia
- Surgical or genetically altered foregut anatomy
- Known gastric outlet obstruction or pre-procedure imaging suggestive of gastric outlet obstruction.
- Patients who did not follow the standard NPO (nil per oral) instructions.
Data sourced from ClinicalTrials.gov (NCT06533527) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.